Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Heron Therapeutics (HRTX) FCF Margin (2016 - 2025)

Historic FCF Margin for Heron Therapeutics (HRTX) over the last 12 years, with Q3 2025 value amounting to 3.48%.

  • Heron Therapeutics' FCF Margin fell 54800.0% to 3.48% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.08%, marking a year-over-year decrease of 135600.0%. This contributed to the annual value of 16.8% for FY2024, which is 306900.0% up from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' FCF Margin is 3.48%, which was down 54800.0% from 29.77% recorded in Q2 2025.
  • Heron Therapeutics' 5-year FCF Margin high stood at 8.96% for Q3 2024, and its period low was 282.08% during Q2 2021.
  • Its 5-year average for FCF Margin is 95.86%, with a median of 84.84% in 2023.
  • As far as peak fluctuations go, Heron Therapeutics' FCF Margin plummeted by -722000bps in 2021, and later skyrocketed by 1782200bps in 2022.
  • Heron Therapeutics' FCF Margin (Quarter) stood at 221.0% in 2021, then soared by 43bps to 126.38% in 2022, then surged by 105bps to 6.44% in 2023, then tumbled by -573bps to 30.45% in 2024, then skyrocketed by 111bps to 3.48% in 2025.
  • Its FCF Margin stands at 3.48% for Q3 2025, versus 29.77% for Q2 2025 and 23.08% for Q1 2025.